Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)

Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Enoxaparin Sodium（RP54563）20mg qd and 20mg Bid for 14 Days in Patients With Total Hip Replacement

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00349180

Enrollment

156

Registered

2006-07-06

Start date

2006-06-30

Completion date

Unknown

Last updated

2009-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthroplasty, Replacement, Hip

Keywords

Total Hip Replacement, Enoxaparin

Brief summary

This study is performed to confirm the optimal dose for THR (total hip replacement).

Interventions

DRUGEnoxaparin sodium

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients undergoing elective primary THR (total hip replacement) surgery

Exclusion criteria

* Patient with risk of clinical significant bleeding

Design outcomes

Primary

Measure	Time frame
Incidence of VTE	—

Secondary

Measure	Time frame
Incidence of bleeding	—

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026